Category: Cancer

Cancer

Blood Test Shows Promise for Detecting Precancerous Ovarian Lesions

Researchers identified an RNA biomarker that detected precancerous fallopian tube lesions with 92.3% sensitivity and 98.2% specificity in a validation cohort.

Cancer

Twist Bioscience Launches Custom MRD Panels for Cancer Assay Development

The new platform offers custom panel manufacturing in as little as one day to support development of tumor-informed MRD assays.

Cancer

AI Model Uses Routine Pathology Slides to Predict Breast Cancer Recurrence Risk

In a study of 372 patients, the model closely matched results from a 70-gene genomic test and identified differences in long-term survival.

Quest, Waters Partner to Expand At-Home HPV Testing with Extended Genotyping

Oct 21, 2026 | Cancer, Cervical (HPV)

Quest Diagnostics and Waters Corp will expand at-home HPV screening nationwide in 2027, offering extended genotyping via the FDA-cleared Onclarity Self-Collection Kit through clinical, health plan, and consumer channels.

Liquid Biopsy Detects Early Lung Cancer Recurrence Months Before Imaging

Oct 21, 2026 | Lung Cancer

A study in The Journal of Molecular Diagnostics found that liquid biopsy tests can detect lung cancer recurrence months before imaging, using ctDNA analysis to monitor relapse risk in early-stage NSCLC patients.

Guardant Health to Highlight Advances in Liquid Biopsy for Cancer Monitoring at ESMO 2026

Oct 20, 2026 | Cancer, Molecular Diagnostics

Guardant Health will present 25 abstracts at ESMO 2026, highlighting new data on ctDNA liquid biopsy for cancer monitoring, including MRD surveillance and therapy resistance in lung, colorectal, and gastric cancers.New research examines how circulating tumor DNA testing could help detect cancer recurrence, track treatment response, and identify resistance across multiple cancer types.

AI Analysis of Pathology Slides Shows Promise for Guiding Lung Cancer Biomarker Testing

Oct 19, 2026 | Analytical Software Systems, Lung Cancer

A study of more than 60,000 lung cancer cases found that AI could predict the presence of 12 biomarkers with more than 80% sensitivity, potentially helping laboratories prioritize additional testing.

Biodesix Partners With Vanderbilt to Develop Lung Cancer Risk Test Combining Blood Tests and Imaging

Oct 19, 2026 | Lung Cancer

Biodesix and Vanderbilt have partnered to develop an AI-powered lung cancer risk test that combines blood-based and imaging biomarkers, with initial data to be presented at RSNA 2026 and commercial launch targeted for 2028.

Collaboration Seeks to Develop Prostate Cancer Companion Diagnostic for Local Lab Testing

Oct 16, 2026 | Prostate

SOPHiA GENETICS and Myriad Genetics are collaborating to develop a decentralized prostate cancer companion diagnostic, aiming to enable local labs to assess DNA repair deficiencies using the PrGIS biomarker in clinical trials.

Clinical Trial Evaluates Blood Test for Early Breast Cancer Detection Alongside Mammography

Oct 16, 2026 | Breast

Keck Medicine of USC has launched a phase 1 trial to assess whether a liquid biopsy detecting rare cells and extracellular vesicles can help identify early-stage breast cancer alongside standard mammography.

New AI Tools Aim to Identify Tissue Samples at Risk of Failed Molecular Testing

Oct 16, 2026 | Anatomic Pathology, Cancer, Digital Pathology

Aignostics has launched HETA Clinical, an AI-based suite for digital pathology that analyzes whole-slide H&E images to assess tumor content and tissue quality, aiming to reduce molecular test failure rates in clinical labs.

Blood-Based Colorectal Cancer Screening Averts More Deaths Than Stool Tests, Modeling Shows

Oct 15, 2026 | Colorectal

A modeling study presented at ACG 2026 projects that blood-based colorectal cancer screening averts more deaths and increases colonoscopy completion rates compared to stool-based methods, according to data from Guardant Health.

Study Validates Cervical Sample Test for Endometrial Cancer Detection

Oct 15, 2026 | Cancer, Cytology, Womens Health

The DNA-based test showed 96.8% specificity in cervical samples and could help physicians determine which patients need further testing for endometrial cancer.

Real-World Evidence from Over 2,000 Patients Supports Routine Blood-Based Lung Nodule Testing

Oct 15, 2026 | Lung Cancer

Biodesix presented data at CHEST 2026 from over 2,000 patients in the CLARIFY study, highlighting how Nodify Lung blood-based testing integrates with PET imaging to improve follow-up adherence for pulmonary nodules.

Why Better Cancer Detection May Depend on Measuring Biomarkers Differently—Not Finding New Ones

Oct 15, 2026 | Cancer

Analyzing the structure of existing biomarkers could reveal new information about cancer, helping laboratories deliver more accurate and clinically useful results.

TissueCypher Identifies Risk of Barrett’s Esophagus Progression Beyond Biopsy Alone

Oct 13, 2026 | Cancer, Histology

Castle Biosciences’ new data presented at ACG 2026 show the TissueCypher test offers objective risk stratification for Barrett’s esophagus progression, providing information beyond standard histopathology.

University Spin-Out Launches to Commercialize Adrenal Cancer and Hormone Disorder Tests

Oct 9, 2026 | Cancer, Diabetes & Metabolic Diseases, Mass Spectrometry

IMS Solutions, a University of Birmingham and Imperial College London spin-out, has raised £1.1 million to commercialize mass spectrometry-based steroid biomarker tests for adrenal cancer and PMOS, with clinical validation underway.

Multi-Omics Blood Test Shows Promise for Early Detection of Three Gynecologic Cancers

Oct 9, 2026 | Cervical (HPV), Womens Health

New data show high diagnostic performance for ovarian, endometrial, and cervical cancers, with a targeted assay designed to run on existing clinical laboratory equipment.